Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Mitra RxDx Announces $40 Million Financing Round

Mitra RxDx
Posted on: 12 Jul 18
Mitra RxDx Announces $40 Million Financing Round CANscript provides powerful predictions for truly personalized cancer treatment selection

PR Newswire

BOSTON, July 11, 2018

BOSTON, July 11, 2018 /PRNewswire/ -- Mitra RxDx (dba Mitra Biotech), a privately held biotech company and global leader in advancing truly personalized oncology treatment, announced today the completion of a $40 million financing round. The round was led by Northpond Ventures, headquartered in Bethesda, Maryland. Existing investors Accel, Sequoia Capital, Sands Capital Ventures, and RA Capital Management also participated. Cumulative funding to date now totals $76 million.

Mitra's CANscript™ platform delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development.

"Northpond is excited to join Mitra, as the CANscript platform has the potential to meaningfully improve how we treat cancer patients," said Michael P. Rubin, M.D., Ph.D., Founder and CEO at Northpond. "We are proud to begin working with the current investors to help Mitra accomplish their clinical and commercial goals." Michael will join existing investor representatives from Accel, Sequoia, Sands, and Tata Capital Innovation Fund on the Mitra board.

"These funds will allow us to expand our commercial efforts, while also continuing to build the clinical evidence necessary to accelerate adoption and secure reimbursement in the U.S. and other key markets," said Mallikarjun Sundaram, President, Co-Founder, and CEO of Mitra. "We enthusiastically welcome Northpond, and greatly appreciate the continued support from our current investors."

About Mitra:
Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India.

The company is led by an accomplished and deeply experienced team of researchers, scientists, and medical commercialization professionals.

To learn more about Mitra, CANscript, or the recent investment round, please contact:

Parker Cassidy
Chief Commercial Officer
Mitra RxDx
12 Gill Street, Suite 3150
Woburn, MA 01801


View original content with multimedia:


PR Newswire

Last updated on: 12/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.